



Geisinger Health Plan Policies and Procedure Manual

Policy: MP256

Section: Medical Benefit Policy

Subject: Transoral Incisionless Fundoplication

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Transoral Incisionless Fundoplication

II. Purpose/Objective:

To provide a policy of coverage regarding Transoral Incisionless Fundoplication

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking

into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:

Transoral Incisionless Fundoplication, including but not limited to the EndoGastric Solutions SerosaFuse™ implantable fasteners, and associated EsophyX delivery device and accessories consist of sterile polypropylene fastener implants and an ergonomic, flexible fastener delivery. The EndoGastric Solutions (EGS) EsophyX™ System with SerosaFuse™ Fastener is indicated for use in endoluminal, transoral tissue approximation, full thickness plication and ligation in the GI tract and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia < 2cm in size in patients with symptomatic chronic gastroesophageal reflux disease.

INDICATIONS: REQUIRES PRIOR AUTHORIZATION BY A PLAN MEDICAL DIRECTOR OR DESIGNEE

COMMERCIAL BUSINESS SEGMENT

Transoral incisionless fundoplication is covered when all of the following criteria are met:

- Member is 18 years of age or greater; and
- A diagnosis of GERD has been established by endoscopy, ambulatory pH testing or barium swallow; and
- Member has a history of daily bothersome GERD symptoms inadequately controlled with individually maximized daily PPI use (unless intolerant to or contraindicated) for at least 6 months; and
- Documentation of gastroesophageal valve (Hill grade I – II) at gastroesophageal junction (**UNLESS** TIF is being done in conjunction with laparoscopic repair of the hiatus)*; and
- Member has a BMI of 35 or less; and
- None of the following are present:
 - Hiatal hernia greater than 2 cm (unless simultaneous or prior repair of hiatal hernia is performed)
 - Esophagitis grade C or D **
 - Barrett's esophagus greater than 2 cm
 - Esophageal ulcer, stricture or narrowing
 - Portal hypertension and/or varices
 - Active gastro-duodenal ulcer
 - Gastric outlet obstruction or stenosis
 - Symptomatically uncontrolled gastroparesis
 - History of uncontrolled or untreated coagulation disorder
 - Cervical spine fusion
 - Zenker's diverticulum

***Note: Hill Classification**

1. Type I hernias are sliding hiatal hernias, where the gastroesophageal junction migrates above the diaphragm. The stomach remains in its usual longitudinal alignment and the fundus remains below the gastroesophageal junction.

2. Type II hernias are pure paraesophageal hernias (PEH); the gastroesophageal junction remains in its normal anatomic position but a portion of the fundus herniates through the diaphragmatic hiatus adjacent to the esophagus.

3. Type III hernias are a combination of Types I and II, with both the gastroesophageal junction and the fundus herniating through the hiatus. The fundus lies above the gastroesophageal junction.

4. Type IV hiatal hernias are characterized by the presence of a structure other than stomach, such as the omentum, colon or small bowel within the hernia sac.

Hill AD, Kozarek RA, Kraemer SJM, Aye RW, Mercer D, Low DE, Pope CE II (1996) The gastroesophageal flap valve: in vitro and in vivo observations. *Gastrointest Endosc* 44: 541–547

**** Los Angeles (LA) Grading of Esophagitis**

- A. Mucosal break(s) ≤5 mm, without continuity across mucosal folds
- B. Mucosal break(s) >5 mm, without continuity across mucosal folds
- C. Mucosal break(s) continuous between ≥2 mucosal folds, involving <75% of the esophageal circumference
- D. Mucosal break(s) involving ≥75% of the esophageal circumference

Katz PO, Gerson LB, et al. Guideline for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol*. 2013;108(3):308-328.

MEDICARE BUSINESS SEGMENT:

Transoral incisionless fundoplication is covered for the following indications:

- Symptomatic chronic gastroesophageal reflux (chronic being defined as > 6 months of symptoms), and
- Symptoms must be responsive to Proton Pump Inhibitors (PPIs) as judged by GERD HRQL scores of < or equal to 12 while on PPIs and > or equal to 20 when off for 14 days (also acceptable would be the difference of > or equal to 10 of the scores between off and on therapy), and
- Hiatal hernia < or equal to 2 cm, if present.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis

Transoral incisionless fundoplication is **NOT** a covered Medicaid benefit. Consideration through a Program Exception is required.

EXCLUSIONS:

The Plan does **NOT** provide coverage for Transoral Incisionless Fundoplication, including but not limited to the EndoGastric Solutions SerosaFuse™ implantable fasteners, and associated EsophyX delivery device, when the criteria for coverage are not met.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Transoral Incisionless Fundoplication

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

43210 – Esophogastroduodenoscopy with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed

43499 – Unlisted procedure, esophagus

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Committee triage group. Transoral Incisionless Fundoplication. May 2011.

Testoni P.A., Corsetti M., et al. Effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refluxes of GERD patients. World journal of surgery 2010;34(4):750-757.

Demyttenaere S.V., Bergman S., et. al. Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surgical Endoscopy and Other Interventional Techniques. 2010;24(4):854-858.

Furnee E.J.B., Broeders J.A.J.L., et al. Laparoscopic nissen fundoplication after failed EsophyX fundoplication. British Journal of Surgery. 2010;97(7):1051-1055.

Velanovich V. Endoscopic, endoluminal fundoplication for gastroesophageal reflux disease: Initial experience and lessons learned. Surgery. 2010;148(4):646-653.

Repici A., Fumagalli U., et al. Endoluminal fundoplication (ELF) for GERD using EsophyX: A 12-month follow-up in a single-center experience. *Journal of Gastrointestinal Surgery*. 2009;14(1):1-6.

Eckardt A.J., Pinnow G., et al. Antireflux 'barriers': Problems with patient recruitment for a new endoscopic antireflux procedure. *European Journal of Gastroenterology and Hepatology*. 2009;21(10):1110-1118.

Jafri S.-M., Arora G., Triadafilopoulos G. What is left of the endoscopic antireflux devices? *Current Opinion in Gastroenterology*. 2009;25(4):352-357.

Cadiere G.-B., Van Sante N., et al. Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. *Surgical Endoscopy and Other Interventional Techniques*. 2009;23(5):957-964.

Cadiere G-B, Buset M. et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. *World J Surg* 2008;32(8):1676-88.

Agency for Healthcare Research and Quality (AHRQ). Treatment options for GERD or acid reflux disease: A review of the research for adults. AHRQ Pub. No.11-EHC049-A. Rockville, MD: AHRQ. September 2011. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/165/756/gerd_consumer.pdf

Cadière GB, Van Sante N, Graves JE, Gawlicka AK, Rajan A. Two-year results of a feasibility study on Antireflux Transoral incisionless fundoplication (TIF) using EsophyX. *Surgical Endoscopy*. 2009; 23 (5): 957-64.

Barnes WE, Hoddinott KM, Mundy S, Williams M.. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. *Surgical Innov* 2011 Feb

Zacherl J, Roy-Shapira A, Bonavina L, et al. Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial. *Surg Endosc*. 2015; 29(1):220-229.

Witte man BP, Conchillo JM, Rinsma NF, et al. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease. *Am J Gastroenterol*. 2015; 110(4):531-542.

Hakansson B, Montgomery M, Cadiere GB, et al. Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD. *Aliment Pharmacol Ther*. 2015; 42(11-12):1261-1270.

Bell RC, Barnes WE, Carter BJ, et al. Transoral incisionless fundoplication: 2-year results from the prospective multicenter U.S. study. *Am Surg*. 2014; 80(11):1093-1105.

Hunter JG, Kahrilas PJ, Bell RC, et al. Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial. *Gastroenterology*. 2015; 148(2):324-333

Wilson EB, Barnes WE, Mavrelis PG, et al. The effects of transoral incisionless fundoplication on chronic GERD patients: 12-month prospective multicenter experience. *Surg Laparosc Endosc Percutan Tech*. 2014; 24(1):36-46.

Trad KS, Barnes WE, Simoni G, et al. Transoral incisionless fundoplication effective in eliminating GERD symptoms in partial responders to proton pump inhibitor therapy at 6 months: the TEMPO Randomized Clinical Trial. *Surg Innov*. 2015; 22(1):26-40.

Lipka S, Kumar A, Richter JE. No evidence for efficacy of radiofrequency ablation for treatment of gastroesophageal reflux disease: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2015; 13(6):1058-1067.

Roy-Shapira A, Bapaye A, Date S, et al. Trans-oral anterior fundoplication: 5-year follow-up of pilot study. *Surg Endosc*. 2015; 29(12):3717-3721

Novitas Solutions, Inc. Local Coverage Determination (LCD): Transoral Incisionless Fundoplication. LCD L34999

Testoni PA, Mazzoleni G, Testoni SG. Transoral incisionless fundoplication for gastro-esophageal reflux disease: techniques and outcomes. *World J Gastrointest Pharmacol Ther*. 2016;7(2):179-89.

Huang X, Chen S, Zhao H, et al. Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: A systematic review with meta-analysis. *Surg Endosc.* 2016 Aug 5

Geisinger Technology Assessment Committee. Transoral Incisionless Fundoplication. April 10, 2019

Trad KS, Fox MA, et al Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm. *Surg Endosc* 2016 DOI 10.1007/s00464-016-5252-8

Sefanidis G, Viazis N, et al. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy. *Diseases of the Esophagus* 2016 DOI: 10.1111/dote.12525

McCarty TR, Itidiare M, et al. Efficacy of transoral incisionless fundoplication for refractory gastroesophageal reflux disease: a systematic review and meta-analysis. *Endoscopy* 2018; 50(7):708-725.

Ihde GM, Pena C, et al. pH Scores in Hiatal Repair with Transoral Incisionless Fundoplication. *JLS.* 2019 Jan-Mar;23(1).

Puri R, Smith CD, Bowers SP. The Spectrum of Surgical Remediation of Transoral Incisionless Fundoplication-Related Failures. *J Laparoendosc Adv Surg Tech A.* 2018 Sep;28(9):1089-1093

ECRI Institute, HTAIS Product brief. EsophyX (Endogastric Solutions, Inc) for treating gastroesophageal reflux disease. Nov. 2018

Hayes Inc Endoscopic therapy for gastroesophageal Reflux Disease. Dec. 2017

Khashab MA, Vela MF, Thosani N, et al. ASGE guideline on the management of achalasia. *Gastrointest Endosc.* 2020; 91(2):213-227.

Yan J, Tan Y, Zhou B, et al. Gastric per-oral endoscopic myotomy (G-POEM) is a promising treatment for refractory gastroparesis: a systematic review and meta-analysis. *Rev Esp Enferm Dig.* 2020; 112(3):219-22

Bernardot L, Roman S, Barret M et al. Efficacy of per-oral endoscopic myotomy for the treatment of non-achalasia esophageal motor disorders. *Surg Endosc.* 2020; 34(12):5508-5515

Mohan BP, Chandan S, Jha LK, et al. Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. *Surg Endosc.* 2020; 34(8):3352-3367.

Chandan S, Mohan BP, Chandan OC, et al. Clinical efficacy of per-oral endoscopic myotomy (POEM) for spastic esophageal disorders: a systematic review and meta-analysis. *Surg Endosc.* 2020; 34(2):707-718.

Kohn GP, Dirks RC, Ansari MT, et al. SAGES guidelines for the use of peroral endoscopic myotomy (POEM) for the treatment of achalasia. *Surg Endosc.* 2021 Feb 9.

Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. *Am J Gastroenterol.* Jan 01 2022; 117(1): 27-56

Rausa E, Ferrari D, Kelly ME, et al. Efficacy of laparoscopic Toupet fundoplication compared to endoscopic and surgical procedures for GERD treatment: a randomized trials network meta-analysis. *Langenbecks Arch Surg.* Jan 21 2023; 408(1): 52

Haseeb M, Brown JRG, Hayat U, et al. Impact of second-generation transoral incisionless fundoplication on atypical GERD symptoms: a systematic review and meta-analysis. *Gastrointest Endosc.* 2023; 97(3):394-406

This policy will be revised as necessary and reviewed no less than annually.

Devised: 6/11

Revised: 12/12 (changed Medicare criteria); 5/19 (Added Commercial Business Segment); 5/20 (revised criteria)

Reviewed: 6/12, 12/13, 12/14, 5/15, 5/16, 4/17, 4/18, 5/21, 5/22, 5/23, 5/24

CMS UM Oversight Committee Approval: 12/23, 7/24

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.